Cohance Lifesciences faces revenue decline but signals milestones for long-term growth

Cohance Lifesciences reports a 23% fall in revenue amid timing and demand challenges, yet highlights strategic wins and pipeline progress that could underpin future recovery and expansion. Cohance Lifesciences said its latest quarter was weighed down by timing shifts and…













